Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Guadecitabine sodium is a inhibitor of second-generation DNA methyltransferases (DNMT) .
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 11,700 | 6-8周 | ||
50 mg | ¥ 15,300 | 6-8周 | ||
100 mg | ¥ 19,500 | 6-8周 |
产品描述 | Guadecitabine sodium is a inhibitor of second-generation DNA methyltransferases (DNMT) . |
体外活性 | HCT116 colorectal carcinoma cells are treated After 6 days, in p16expression is observed with Guadecitabine sodium (SGI-110 sodium) show a dose-dependent increase . In addition, a dose-dependent increase in the level of p16 protein in T24 and HCT116 cells treated with Guadecitabine sodium or 5-aza-CdR for 3 days, showing the competence of Guadecitabine sodium to inhibit DNA methylation and induce p16 at both mRNA and protein levels as well as 5-aza-CdR. Thus, Guadecitabine sodium is able to inhibit DNA methylation at 5′-region and induce the expression of the p16 gene in T24 and HCT116 cells at concentrations comparable to 5-aza-CdR, and the induction of p16 expression by both agents correlates with the demethylation at the 5′-end region of the gene in both cell lines. Guadecitabine sodium is slightly less toxic than 5-aza-CdR at the doses tested up to 1 μM concentration but displaying similar toxicity at 10 μM concentration[1]. |
体内活性 | Guadecitabine sodium(10mg/kg )is an effective dose at reducing DNA methylation and retarding tumor growth, and caused roughly the same level of toxicity as 5-Aza-CdR. Guadecitabine sodium is effective in vivo at reactivating the expression of the p16 gene, which is heavily methylated in the parent EJ6 cells. Guadecitabine sodium is effective in reducing the level of DNA methylation in vivo at the p16 promoter region. Guadecitabine sodium is better tolerated than 5-Aza-CdR in vivo[2]. |
别名 | SGI-110 sodium, S-110 sodium |
分子量 | 580.407 |
分子式 | C18H24N9NaO10P |
CAS No. | 929904-85-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (86.30 mM), Sonification is recommended.
H2O: Soluble
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.7229 mL | 8.6146 mL | 17.2293 mL | 43.0732 mL |
5 mM | 0.3446 mL | 1.7229 mL | 3.4459 mL | 8.6146 mL | |
10 mM | 0.1723 mL | 0.8615 mL | 1.7229 mL | 4.3073 mL | |
20 mM | 0.0861 mL | 0.4307 mL | 0.8615 mL | 2.1537 mL | |
50 mM | 0.0345 mL | 0.1723 mL | 0.3446 mL | 0.8615 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Guadecitabine sodium 929904-85-8 Chromatin/Epigenetic DNA Methyltransferase SGI-110 sodium S-110 sodium Inhibitor inhibitor inhibit